Published in Am J Gastroenterol on November 01, 2001
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut (2002) 2.16
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci (2010) 1.65
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2006) 1.42
Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc (2014) 1.41
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis (2003) 1.39
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget (2015) 1.15
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol (2009) 1.08
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst (2003) 0.99
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98
Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res (2008) 0.98
Elastic scattering spectroscopy for detection of cancer risk in Barrett's esophagus: experimental and clinical validation of error removal by orthogonal subtraction for increasing accuracy. J Biomed Opt (2009) 0.96
Different perceptions of the burden of upper GI endoscopy: an empirical study in three patient groups. Qual Life Res (2007) 0.96
HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med (2008) 0.95
Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One (2012) 0.94
Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Mol Cytogenet (2012) 0.93
Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer (2010) 0.91
Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. BMC Clin Pathol (2008) 0.89
Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer (2008) 0.89
Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. Br J Cancer (2010) 0.89
Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol (2012) 0.89
Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia (2005) 0.88
Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus. Br J Cancer (2011) 0.88
Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prev Res (Phila) (2015) 0.87
Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol (2010) 0.87
Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity. Cancer Biomark (2009) 0.87
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med (2014) 0.84
Current Strategies in the management of Barrett's esophagus. Curr Gastroenterol Rep (2005) 0.84
Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments. J Gastrointest Oncol (2012) 0.83
Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83
Can oncology recapitulate paleontology? Lessons from species extinctions. Nat Rev Clin Oncol (2015) 0.82
Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.82
Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma. Hosp Pract (1995) (2011) 0.82
Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. PLoS One (2012) 0.82
Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol (2009) 0.82
High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett's Esophagus. PLoS One (2015) 0.81
Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology (2015) 0.81
Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol (2013) 0.81
Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. Dig Dis Sci (2015) 0.79
Management strategies of Barrett's esophagus. World J Gastroenterol (2012) 0.79
Establishment of proliferative tetraploid cells from normal human fibroblasts. Front Oncol (2013) 0.79
Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79
"Indefinite for Dysplasia" in Barrett's Esophagus: Inflammation and DNA Content Abnormality are Significant Predictors of Early Detection of Neoplasia. Clin Transl Gastroenterol (2015) 0.79
Narrow-band imaging: the significance of detail. Gastroenterol Hepatol (N Y) (2008) 0.79
Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78
Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus (2013) 0.78
Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med (2008) 0.78
Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective. Cell Mol Gastroenterol Hepatol (2017) 0.77
Biomarkers of Barrett's esophagus. World J Gastrointest Pathophysiol (2014) 0.77
GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers? Gastroenterol Res Pract (2013) 0.77
The molecular basis of carcinogenesis in Barrett's esophagus. J Gastrointest Surg (2010) 0.77
Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett's Esophagus Cohort. PLoS One (2015) 0.76
Open questions in oesophageal adenocarcinogenesis. Gut (2007) 0.76
Surrogate Markers: Lessons from the Next Gen? Cancer Prev Res (Phila) (2016) 0.75
Endoscopic Imaging in Barrett's Oesophagus: Applications in Routine Clinical Practice and Future Outlook. Clin Endosc (2011) 0.75
Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol (2006) 0.75
Asymmetric aneuploidy in mesenchymal stromal cells detected by in situ karyotyping and fluorescence in situ hybridization: suggestions for reference values for stem cells. Stem Cells Dev (2015) 0.75
Managing Barrett's esophagus with radiofrequency ablation. Gastroenterol Rep (Oxf) (2013) 0.75
Extensive telomere erosion is consistent with localised clonal expansions in Barrett's metaplasia. PLoS One (2017) 0.75
Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective. Gastrointest Cancer Res (2008) 0.75
Biomarkers in Barrett's Esophagus. Tech Gastrointest Endosc (2010) 0.75
Barrett's Esophagus: Diagnosis and Management. Gastrointest Endosc (2017) 0.75
Low grade dysplasia in Barrett's esophagus: Should we worry? World J Gastrointest Pathophysiol (2014) 0.75
[Subjective grading of Barrett's neoplasia by pathologists: correlation with objective histomorphometric variables]. Pathologe (2013) 0.75
[Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy]. Pathologe (2011) 0.75
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer (2017) 0.75
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
ROC methodology in radiologic imaging. Invest Radiol (1986) 7.55
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol (1997) 4.52
The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med (1985) 4.30
Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol (1998) 3.88
Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67
Barrett's esophagus. N Engl J Med (1986) 3.62
Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology (1984) 3.36
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut (1996) 2.75
Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA (1993) 2.71
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol (1999) 2.50
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology (1999) 2.46
Prevalence of metaplasia at the gastro-oesophageal junction. Lancet (1994) 2.45
Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science (1987) 2.35
Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut (1991) 2.29
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol (1999) 2.26
Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg (1994) 2.25
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med (1991) 2.01
Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg (1988) 1.91
Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest (1989) 1.83
Model for the genetic evolution of human solid tumors. Cancer Res (1989) 1.82
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
p53-mutant clones and field effects in Barrett's esophagus. Cancer Res (1999) 1.61
Accessibility of DNA in situ to various fluorochromes: relationship to chromatin changes during erythroid differentiation of Friend leukemia cells. Cytometry (1984) 1.60
Barrett's esophagus: does the incidence of adenocarcinoma matter? Am J Gastroenterol (1997) 1.58
TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology (1994) 1.50
Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc (1999) 1.45
Mammalian G1 and G2 phase checkpoints. Cancer Surv (1997) 1.41
Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control (1996) 1.35
Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology (1992) 1.30
The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol (1988) 1.24
Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res (2000) 1.18
Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. Mutat Res (1996) 1.15
Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer (1998) 1.14
Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry (1993) 1.13
Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol (1998) 1.09
Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry (1984) 1.09
Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology (1978) 1.08
Cell proliferation in three types of Barrett's epithelium. Gut (1980) 1.08
Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci (1989) 1.06
The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer (1994) 1.05
Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol (2000) 1.01
[Reproducibility of histological criteria of dysplasia in Barrett mucosa]. Gastroenterol Clin Biol (1994) 1.00
Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet (1986) 0.90
DNA profile and tumour progression in patients with superficial bladder tumours. Urol Res (1982) 0.90
A model of DNA aneuploidization and evolution in colorectal cancer. Lab Invest (1994) 0.90
Surveillance for Barrett's esophagus: are we saving lives? Gastroenterology (1997) 0.87
[Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases]. Gastroenterol Clin Biol (1991) 0.86
The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Pathol (1989) 0.86
Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms. Cytometry (1989) 0.85
Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry (1993) 0.83
The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer. J Urol (1988) 0.82
The economic impact of the diagnosis of dysplasia in Barrett's esophagus. Am J Gastroenterol (2000) 0.82
Characterization of hematologic malignancies by flow cytometry. Anal Quant Cytol Histol (1987) 0.80
Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. Cancer Res (1989) 0.78
Barrett's esophagus. The cytology of dysplasia in comparison to benign and malignant lesions. Acta Cytol (1992) 0.78
Genetic control of the cell division cycle in yeast. Science (1974) 13.83
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
On estimating HLA/disease association with application to a study of aplastic anemia. Biometrics (1991) 4.81
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Regulation of mating in the cell cycle of Saccharomyces cerevisiae. J Cell Biol (1977) 3.68
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 2.58
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res (2000) 2.13
Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13
p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology (1992) 2.03
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol (1986) 1.91
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res (1999) 1.90
Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest (1989) 1.83
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res (1997) 1.67
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology (1998) 1.65
p53-mutant clones and field effects in Barrett's esophagus. Cancer Res (1999) 1.61
c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology (1990) 1.59
Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol (1999) 1.59
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
A neural network theory of proportional analogy-making. Neural Netw (2000) 1.53
Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci U S A (1991) 1.53
17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res (1994) 1.52
Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res (1994) 1.49
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol (1996) 1.47
Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene (1996) 1.46
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology (1994) 1.43
Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A (1993) 1.40
17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res (1991) 1.39
Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev (1996) 1.39
Incorporating the time dimension in receiver operating characteristic curves: a case study of prostate cancer. Med Decis Making (1999) 1.38
Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene (1996) 1.32
Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol (2000) 1.25
Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology (1990) 1.24
Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Nucleic Acids Res (1995) 1.24
Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology (1998) 1.24
A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med (1997) 1.19
Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol (1990) 1.17
Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res (1996) 1.14
Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology (1991) 1.11
Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol (1988) 1.10
High-quality RNA and DNA from flow cytometrically sorted human epithelial cells and tissues. Biotechniques (2002) 1.08
The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer (1994) 1.05
Neural dynamics of attentionally modulated Pavlovian conditioning: blocking, interstimulus interval, and secondary reinforcement. Appl Opt (1987) 1.04
Multiple keratoacanthomata. A unique case and review of the current classification. Acta Derm Venereol (1978) 1.04
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant (2001) 1.01
Inflammatory polyposis two years after ischemic colon injury. Dig Dis Sci (1986) 1.00
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1999) 0.99
Impact of composting strategies on the treatment of soils contaminated with organic pollutants. Environ Pollut (2001) 0.99
Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res (1991) 0.99
Specialized metaplastic columnar epithelium in Barrett's esophagus. A comparative transmission electron microscopic study. Lab Invest (1989) 0.99
Barrett's esophagus and adenocarcinoma. Annu Rev Med (1987) 0.99
Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. Gastroenterology (1989) 0.97
Biomarkers in Barrett esophagus. Mayo Clin Proc (2001) 0.97
Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc (1991) 0.97
Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res (1992) 0.97
Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol (1994) 0.97
Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood (1992) 0.97
Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer (2000) 0.94